|
1
|
Khan N, Afaq F and Mukhtar H: Apoptosis by
dietary factors: the suicide solution for delaying cancer growth.
Carcinogenesis. 28:233–239. 2007. View Article : Google Scholar
|
|
2
|
Liekens S: Regulation of cancer
progression by inhibition of angiogenesis and induction of
apoptosis. Verh K Acad Geneeskd Belg. 70:175–191. 2008.PubMed/NCBI
|
|
3
|
Chen Y, Wang Y, Song H, Wang J, Yang H,
Xia Y, Xue J, Li S, Chen M and Lu Y: Expression profile of
apoptosis-related genes potentially explains early recurrence after
definitive chemoradiation in esophageal squamous cell carcinoma.
Tumour Biol. 35:4339–4346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu H, Wang Y, Zhang Y, Song Q, Di C, Chen
G, Tang J and Ma D: TFAR19, a novel apoptosis-related gene cloned
from human leukemia cell line TF-1, could enhance apoptosis of some
tumor cells induced by growth factor withdrawal. Biochem Biophys
Res Commun. 254:203–210. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen Y, Sun R, Han W, Zhang Y, Song Q, Di
C and Ma D: Nuclear translocation of PDCD5 (TFAR19): an early
signal for apoptosis? FEBS Lett. 509:191–196. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Du YJ, Xiong L, Lou Y, Tan WL and Zheng
SB: Reduced expression of programmed cell death 5 protein in tissue
of human prostate cancer. Chin Med Sci J. 24:241–245. 2009.
View Article : Google Scholar
|
|
7
|
Spinola M, Meyer P, Kammerer S, Falvella
FS, Boettger MB, Hoyal CR, Pignatiello C, Fischer R, Roth RB,
Pastorino U, Haeussinger K, Nelson MR, Dierkesmann R, Dragani TA
and Braun A: Association of the PDCD5 locus with lung cancer risk
and prognosis in smokers. J Clin Oncol. 24:1672–1678. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang X, Wang X, Song X, Wei Z, Zhou C,
Zhu F, Wang Q, Ma C and Zhang L: Clinical and prognostic
significance of lost or decreased PDCD5 expression in human
epithelial ovarian carcinomas. Oncol Rep. 25:353–358. 2011.
View Article : Google Scholar
|
|
9
|
Li H, Wang Q, Gao F, Zhu F, Wang X, Zhou
C, Liu C, Chen Y, Ma C, Sun W and Zhang L: Reduced expression of
PDCD5 is associated with high-grade astrocytic gliomas. Oncol Rep.
20:573–579. 2008.PubMed/NCBI
|
|
10
|
Ruan GR, Qin YZ, Chen SS, Li JL, Ma X,
Chang Y, Wang YZ, Fu JY and Liu YR: Abnormal expression of the
programmed cell death 5 gene in acute and chronic myeloid leukemia.
Leuk Res. 30:1159–1165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yin A, Jiang Y, Zhang X, Zhao J and Luo H:
Transfection of PDCD5 sensitizes colorectal cancer cells to
cisplatin-induced apoptosis in vitro and in vivo. Eur J Pharmacol.
649:120–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu HY, Chen ZW, Pan YM, Fan L, Guan J and
Lu YY: Transfection of PDCD5 effect on the biological behavior of
tumor cells and sensitized gastric cancer cells to
cisplatin-induced apoptosis. Dig Dis Sci. 57:1847–1856. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H, Zhang X, Song X, Zhu F, Wang Q, Guo
C, Liu C, Shi Y, Ma C, Wang X and Zhang L: PDCD5 promotes
cisplatin-induced apoptosis of glioma cells via activating
mitochondrial apoptotic pathway. Cancer Biol Ther. 13:822–830.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo XL, Ma NN, Zhou FG, Zhang L, Bu XX,
Sun K, Song JR, Li R, Zhang BH, Wu MC and Wei LX: Up-regulation of
hTERT expression by low-dose cisplatin contributes to chemotherapy
resistance in human hepatocellular cancer cells. Oncol Rep.
22:549–556. 2009.PubMed/NCBI
|
|
15
|
Asechi H, Hatano E, Nitta T, Tada M,
Iwaisako K, Tamaki N, Nagata H, Narita M, Yanagida A, Ikai I and
Uemoto S: Resistance to cisplatin-induced apoptosis via
PI3K-dependent survivin expression in a rat hepatoma cell line. Int
J Oncol. 37:89–96. 2010.PubMed/NCBI
|
|
16
|
Ando T, Kawabe T, Ohara H, Ducommun B,
Itoh M and Okamoto T: Involvement of the interaction between p21
and proliferating cell nuclear antigen for the maintenance of G2/M
arrest after DNA damage. J Biol Chem. 276:42971–42977. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Selvendiran K, Tong L, Vishwanath S,
Bratasz A, Trigg NJ, Kutala VK, Hideg K and Kuppusamy P: EF24
induces G2/M arrest and apoptosis in cisplatin-resistant human
ovarian cancer cells by increasing PTEN expression. J Biol Chem.
282:28609–28618. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weir NM, Selvendiran K, Kutala VK, Tong L,
Vishwanath S, Rajaram M, Tridandapani S, Anant S and Kuppusamy P:
Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant
human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer
Biol Ther. 6:178–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu XL, Xing BC, Han HB, Zhao W, Hu MH, Xu
ZL, Li JY, Xie Y, Gu J, Wang Y and Zhang ZQ: The properties of
tumor-initiating cells from a hepatocellular carcinoma patient’s
primary and recurrent tumor. Carcinogenesis. 31:167–174. 2010.
View Article : Google Scholar
|
|
20
|
Yao H, Feng Y, Zhou T, Wang J and Wang ZX:
NMR studies of the interaction between human programmed cell death
5 and human p53. Biochemistry. 51:2684–2693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu L, Hu J, Zhao Y, Hu J, Xiao J, Wang Y,
Ma D and Chen Y: PDCD5 interacts with p53 and functions as a
positive regulator in the p53 pathway. Apoptosis. 17:1235–1245.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fransvea E, Mazzocca A, Antonaci S and
Giannelli G: Targeting transforming growth factor (TGF)-betaRI
inhibits activation of beta1 integrin and blocks vascular invasion
in hepatocellular carcinoma. Hepatology. 49:839–850. 2009.
View Article : Google Scholar
|
|
23
|
Wang J, Guan Z and Ge Z: Plasma and
synovial fluid programmed cell death 5 (PDCD5) levels are inversely
associated with TNF-α and disease activity in patients with
rheumatoid arthritis. Biomarkers. 18:155–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang JF, Guan ZP, Zhang SL, Pei Z, Chen YY
and Pan H: Programmed cell death 5 correlates with disease activity
and interleukin-17 in serum and synovial fluid of rheumatoid
arthritis patients. Chin Med J (Engl). 126:296–299. 2013.
|
|
25
|
Yu H, Pan C, Zhao S, Wang Z, Zhang H and
Wu W: Resveratrol inhibits tumor necrosis factor-alpha-mediated
matrix metalloproteinase-9 expression and invasion of human
hepatocellular carcinoma cells. Biomed Pharmacother. 62:366–372.
2008. View Article : Google Scholar
|
|
26
|
Li J, Lau GK, Chen L, Dong SS, Lan HY,
Huang XR, Li Y, Luk JM, Yuan YF and Guan XY: Interleukin 17A
promotes hepatocellular carcinoma metastasis via NF-κB induced
matrix metalloproteinases 2 and 9 expression. PLoS One.
6:e218162011. View Article : Google Scholar
|
|
27
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Graham TR, Zhau HE, Odero-Marah VA,
Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW and O’Regan
RM: Insulin-like growth factor-I-dependent up-regulation of ZEB1
drives epithelial-to-mesenchymal transition in human prostate
cancer cells. Cancer Res. 68:2479–2488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yi C, Ma C, Xie Z, Zhang G, Song W, Zhou X
and Cao Y: Down-regulation of programmed cell death 5 by
insulin-like growth factor 1 in osteoarthritis chondrocytes. Int
Orthop. 37:937–943. 2013. View Article : Google Scholar : PubMed/NCBI
|
